TechInvention Lifecare invests $15 M into global collaborative centre for medical countermeasures in Navi Mumbai

26 February 2024 | News

To serve the needs of both public and private organisations

image credit- shutterstock

image credit- shutterstock

In a significant stride towards enhancing global health security and pandemic preparedness, TechInvention Lifecare has announce the ground breaking of its Global Collaborative Centre for Medical Countermeasures (GCMC) with an investment of approx. $15 million. The centre is strategically located close to the upcoming international airport in Navi Mumbai.

GCMC has been acknowledged for its global significance at the 2nd World Local Production Forum in The Hague on 6-8 November 2023, organised by the WHO. The objective of GCMC is well aligned to WHO’s call to action, CEPI’s 100 days mission, India’s National Biotechnology Development Strategy (2020-2025), and other global key initiatives.

This facility will serve the needs of both public and private organisations, such as academic institutes, startups, MSMEs, and R&D organisations, to provide a comprehensive ecosystem, facilitating the transition from R&D to GMP-scale production for pre-clinical/clinical batches with required regulatory approvals. 

GCMC is a unique eco-friendly centre to cater to crucial medical countermeasures, the entire cycle of vaccine development, from strain to supply, biotherapeutics and diagnostics for both human and veterinary segments, while ensuring sustainable manufacturing. 

Syed S. Ahmed, Director and CEO of TechInvention, said, “The current challenges posed in biologics equity arise from the disparity in translational research dissemination from the centres of excellence to the regional manufacturing ‘hub and spoke’ model setups. We believe that GCMC would be the needed intervention, strengthening the hubs by providing ‘scaled-up’, regulatory-approved, cost-effective, and free of IP infringement Biosolutions sourced from both indigenous research and centres of excellence worldwide”.



× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account